Merck Sharp & Dohme Corp to augment HPV vaccine supplies to China

The supply of much-sought-after human papillomavirus or HPV vaccine to China will be "remarkably "increased within this year to meet unfulfilled demand in the Chinese market, executives of Merck Sharp& Dohme Corp, a US-based pharmaceutical company, said.

The firm is known as Merck& Co Inc in the United States and Canada. Merck has been proactively cooperating with "internal and external partners", and has adopted a range of strategies to increase HPV vaccine supplies.

It will leverage its global distribution network and expanding production to serve the Chinese market better, according to its China branch.